7-[(R)-2-((E)-3-hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-hept-5-ynoic acid | 802906-89-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-[(R)-2-((E)-3-hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-hept-5-ynoic acid
• 英文别名: 7-[(2R)-2-[(E)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]hept-5-ynoic acid
• CAS: 802906-89-4
• 化学式: C₂₂H₂₇NO₄
• 分子量: 369.461
• InChiKey: GJIPLJLKSBEBFZ-RKUIQBLJSA-N

物化性质

• 沸点：
  616.2±55.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-碘代丙烷 、 7-[(R)-2-((E)-3-hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-hept-5-ynoic acid 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 在 盐酸 、 碳酸氢钠 、 Brine 、 Sodium sulfate-III 、 silica gel 、 二氯甲烷 、 methanol-dichloromethane 作用下， 以 丙酮 、 乙酸乙酯 为溶剂， 反应 18.08h， 以afforded 13 mg (47%) of the title compound的产率得到7-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-hept-5-ynoic acid isopropyl ester
  参考文献：
  名称：

  Treatment of inflammatory bowel disease

  摘要：

  本发明提供了一种治疗炎症性肠病的方法，其包括向患有眼压增高或青光眼的动物施用有效治疗量的哌啶基前列腺素E类似物。

  公开号：

  US07326716B2

文献信息

• Piperidinyl prostaglandin E analogs
  申请人：ALLERGAN, INC.

  公开号：US20040248854A1

  公开（公告）日：2004-12-09

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein X, Y, Z, D and R 3 are as defined in the specification. Also disclosed are compounds comprising 2 or a pharmaceutically acceptable salt or a prodrug thereof; wherein A, X, J, and R 3 are as defined in the specification. Also disclosed are compounds having an &agr; and an &ohgr; chain comprising 3 or derivatives thereof, as defined in the specification or pharmaceutically acceptable salts or prodrugs thereof.

  本发明提供了一种治疗眼压增高或青光眼的方法，包括向患有眼压增高或青光眼的动物施用一定剂量的通式I代表的化合物；其中X、Y、Z、D和R3如规范中定义。还披露了包括2或其药用盐或前药的化合物；其中A、X、J和R3如规范中定义。还披露了具有α和ω链的化合物，包括3或其衍生物，如规范中定义，或其药用盐或前药。
• PIPERIDINYL PROSTAGLANDIN E ANALOGS
  申请人：ALLERGAN, INC.

  公开号：EP1631355A1

  公开（公告）日：2006-03-08
• TREATMENT OF INFLAMMATORY BOWEL DISEASE
  申请人：ALLERGAN, INC.

  公开号：EP1817033A1

  公开（公告）日：2007-08-15
• THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS
  申请人：ALLERGAN, INC.

  公开号：US20130245283A1

  公开（公告）日：2013-09-19

  A compound comprising a prodrug of a prostaglandin EP 4 agonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a therapeutically effective amount of a prostaglandin EP 4 agonist to a colon of a mammal is also disclosed herein. Dosage forms, medicaments, and compositions, related thereto are also disclosed.
• SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS
  申请人：Allergan, Inc.

  公开号：US20140142042A1

  公开（公告）日：2014-05-22

  A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars.